Member Info for Runner-Runner

Hi Cityone

They are affimers bud. No "r".

Yes Doh, I reckon we are at about fair value where we are. But ironically that fair value is still based on the guessing game of "do affimers offer proven significat benefits over antibodies".

If the answer to that question is "no", then the SP is likely overvalued somewhat.

If our tests do indeed come online, are best in class (thanks to affimers), then the value becomes enormous.

On the one hand you have the covid testing value. And on the other, the value increase in the affimer IP itself (which would dwarf the testing value once proven).

It really is this important that these tests are as good as Al has been saying.

That is what gets me excited about this company. Not Friday FOMO, or any of the other short term shyte that goes on in here.

CS

If Affimers prove to be the real deal. We cannot stop a takeover IMO. The biggest pharma are too rich, too powerrful and too greedy to not want it all for themselves.

It is also why al missing timelines and dishing out fluffy comms makes me wince.

When he finally announces to the world that Affimers are the new Kings of the Biotech jungle. I need him to still be believable!

Absolutely.

I believe the boardrooms of the biggest pharma giants out there have had Avacta and their affimers on their radar for some time. They are likely doing a coule of things.

1. Monitoring closely how affimers perform, with a view to acquiring them as soon as they feel the time is right. The longer they wait, the more expensive it will be - so, it really could be quick, but these Affimers have got to "damn well work".
2. Very likely trying to produce their own alternatives, now they are aware that Antibodies can be replaced.

This is why I posted the other day that for me, it isn't about getting these tests out ASAP. it is about proving to the world that Affimers are next gen.

I think that is why AS is taking all the time he needs to get this right.

Doh,

" In my mind the value here isn’t the tests (though huge sales would obviously make the SP rocket) but confirmation of how useful Affimers are"

This is what the long termers are here for. The real value driver of this business aint covid tests, or even the cancer theraputics - as huge as these could be on their own.

It is the value that affimers could bring to a company that has the resources to get the most out of them in the quickest way. That company isn't Avacta, but one of the giants out there.

The affimer IP is the key. But as you say. We need the cold hard proof that they are as good as AS claims.

We are closing in on the truth, one way or another IMO.

TBH Doh, I think I should decide what i should worry about!

Doh. I have to say. You have been a breath of fresh air to this board. Despite our little spat tonight, I have found you to be an honest - tell 'em like it is and very funny contibutor. Long may that continue. In the spirit of being honest you have definately been more prone to dishing out some "unfair" outbursts of late. I know it is impossible for you to know, or for me to prove but I promise you if you knew me, our spat tonight would have been just a great Avacta debate. With a "lorra lorra laughs".

That is the sad thing about this board. The annonymity breeds mistrust and contempt.

I, by nature do not say alot, either in here or in "real life" which is why i have been a lurker. I guess I'd better go back into hibernation again.

Good luck all genuine investors here. Long, short, fat, thin and all.

I never said what level my "concerns" were, Doh. So not sure why you are making such a fuss over them for. Really don't know why you are in such a state about them really. They are mine after all. unless you think that by some Uri Gellar type mind skills, my "concerns" can somehow "bend" the shareprice the wrong way.

No Zoom.

I originally invested at 27p.

Obviouslu at 13p I was more than a little "concerned" lol as i was 60% down!

However, I trusted my research and my instincts and bought more. Not as much as I would have liked at 13p, but then I was bricking it a little.

Very soon after the Kamani's bought in and all hell broke loose on the other board. i was one of the few that thought it was a good idea at the time so began loading up heavily at leveles from 18p to 45p.

It has been a thrilling and at times stomach churning ride. But, you gotta go with your gut. And I am still here. Planning to top slice at some point, but keeping the bulk for what I believe will be a takeover at some point.

Doh,

Not sure why you think totally misrepresenting my posts and "concerns" is cool.

There was a lot of speculation on the "other" board (adfn) that Avacta may be getting into the covid race. I actually posted at the time that I felt is was a risk to their long term strategy.

Believe it or not Doh. There are people invested here that decided this company had a great future before you.

Doh.

You seem to be in need of a lie down Sir.

And Booooom!

The Dohtard jumps in with another blindside attack of infantile ear bashing demands.

I am very nicely in profit. I did manage to buy some at 13p since you mention it. Along with plenty more in the 16 - 45p range. What was stopping me selling at £2? Well, I am a LTH you see. I believe the IP will be worth much much more in the long term. What exactly are you so ****ing angry about?

ZZtop. I absolutely believe in Avacta and their affimer IP. I said the next 5 weeks are massive if they are going to deliver the huge revenues from covid testing that have been so hyped on here by the covid chasers and also that Al doesn't miss another important timeline.

Zoom,
And I am just saying you look very stupid for saying it, given my position here and when I took the buk of it.

What is with this ridiculous idea that all LTH's should be happy-clappy with everything the company says or does? A silly mistake, a badly missed timeline or an unfulfilled promise can cause just as much damage to a LTH as anyone. And by defination we don'y buy into the nonsense hype spouted by the short termers and day traders.

I quote below Sujood from just before 3 today. the kind of post that drives me nuts.

"Hit that buy button
All this leaky
Buys are going to go mental before close. Blue finish today. Last chance at these rates I imagine."

I rest my case.

Yes Zoom, I am indeed short.

All 5 foot 7 of me.

Negative history? Nope.

Do I ramp the hell out of the company on a daily basis with ridiculous assumptions pulled out of thin air? Nope.

Do I like it when Al badly misses timelines? Nope. Do any of you?

I am a LTH wether you decide to make yourself look stupid (if only to me) by believing otherwise. I was concerned that going down the covid route might be a costly distraction to the main business - I still am to a point.

As a LTH I really really want Al to stop missing timelines and to stop issueing fluffy comms to the market.

CS - apologies for the long post!

Delivering the test at all, even if it it Easter next year will still be an incredible achievement for Avacta, even if it isn't a mammoth money spinner on it's own. It was a £20m company with about £5m in the kitty when they decided to give it a go. So, monumental cudos to the team if they get it out to the required spec at any time in the future. But Al really needs to not miss any more timelines for all our sakes. And I say that with a long term view here.

For me, proving affimers have clear advantages is the real future money spinner and I was invested long before covid was swirling round a chinese market. Being a LTH makes the madness on here even harder to read.

As another "it must be us" assumption bites the dust, isn't it now time to sit back and wait for the company to deliver the news themselves? And also to start to prepare for the possibilty that news may not be good.

It has been an uneasy ride on the Avacta bus & we haven't helped ourselves with the constant fantasy dot joining.

3 months or so ago Trump turned to Fauci talking of a gamechanger in testing we will hear about soon. This place lit up like a christmas tree and the madness began. All this time later and we still don't have a test on the market. ( let's not kid ourselves the bams and elisa research tests count) The idea Trump was actually talking about us was verging on insanity. When "pregnancy style" LFT's were first mooted in parliament, our Government were obviously talking about Avacta. More time has shown that they almost certainly were not. Or by no means exclusively. They clearly already had eyes and open chequebooks for the innova test.

That madness seems to be as endemic on this board as the Virus is on the planet, as even today, some people actually thought the Ringwood trial was us, when we all know Avacta hasn't a finalised product yet.

Boris has a huge stockpile of LFT's he is happy with (innova). Abbot will be next. Which brings me neatly on to the big topic of the last few weeks. the "sovereign test". The certainty with which some members of this board ramped this idea as being us, could lead to more pain.

It surely isn't beyond the realms of possibilty that the UK government are considering procuring the innova test tech and manufacturing in this country to pass off as a Sovereign test.

Lots of "missing the boat" posts of the last 8 weeks or so have been met with derision and abuse.

It is clear that the first boat has indeed sailed off with £100's of millions of UK government money. Money that would have been Avacta's if Alistair had delivered on his placing manifesto. It's no good saying Innova can't produce all that's needed. The Chinese have far more manufacturing capacity at lower cost than Avacta could ever hope to achieve.

Every day that passes the world of Covid testing moves on apace and Avacta's dream machine gathers more dust.

If affimers really were the answer to detecting covid, why oh why didn't we just licence them out in their billions for others to produce the tests in the first place? Or, maybe like with the neutralising affimers, we tried. And like with the neutralsing affimers, nobody wanted them. I really do think Alistair thought he could deliver. However, the sands of time are indeed running very low.

Not delivering tech transfer in Q4, I think would finally put to bed any thoughts of generating huge revenues from Covid testing for Avacta IMO and of course losing more investor confidence in Alistair's vision. Massive 5 weeks for us all.

Have gone through a number of RNS's from since I first invested. Dates/reason for RNS below and some of the comments made by the company which have not been wholly accurate in hindsight. Interesting and dissapointing at the same time.

10th October 2018 New England Biolabs Affimer reagent licensing deal.
Avacta will receive a royalty on product sales, which may occur as soon as 2019.

10th December 2018. LG Chem Deal.
the Group expects to advance its lead programme, a PD-L1/LAG3 bispecific, into the clinic in 2020.

21st January 2019 Business Update

Multiple further licensing deals expected through 2019. I look forward to updating the market on progress during 2019 which I expect to be a year of very significant progress for the Company."

9th April 2019 Interims

First-time-in-human data is a significant value inflection point for the technology and a major de-risking point from a deal making perspective. The Group remains on track, to a tight schedule, to dose first patients in late 2020.

3 June 2019 TMAC Programme Accelerates

Key linker element of Avacta's novel TMACTM drug conjugate to be tested in humans within 12 months.

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that it is planning to submit an IND/CTA application early in 2020 to test the TMAC linker in a phase I study in patients with selected solid tumours.

In an acceleration of the TMAC programme, Avacta is now in a position to test this critical TMAC linker in humans, a major de-risking milestone for the programme, early in 2020 and well ahead of its original plan.

18 October 2019 Interims
Acceleration of Tufts collaboration with planned regulatory submission in the first quarter of 2020.
7 diagnostics evaluations including 4 with top 10 global in vitro diagnostic companies all of which could lead to licensing deals.
14 projects with pharma and biotech companies including 4 out of the top 10 large pharma.

2 evaluations with bioprocessing companies, one being a global leader in affinity purification, and both with the potential to deliver licensing deals.

AVA6000 pro-Doxorubicin that is based on the Tufts technology, we have seen a dramatic improvement in safety in pre-clinical animal models. If we see a similar reduction in cardiotoxicity in humans in the planned phase I clinical trial of AVA6000 in 2020

23 Jan 2020 Trading Update
We are also due to take our first drug AVA6000, a re-engineered form of the chemotherapy Doxorubicin into the clinic in the middle of 2020, making it a ground-breaking yearfor the Group. The initial readout, which aims to show that the side effects of this chemotherapy have been reduced, are expected before the end of the year.
2nd April 2020 £2m Placing
Avacta will file a CTA application as soon as possible for a phase I dose escalation study for its lead preCISION pro-drug chemotherapy AVA6000 pro-doxorubicin.
From here came the Covid Rapid

I'm guessing you aint getting much sleep at the moment PC?

"You can feel it. It’s about to explode!!!!"

The only thing about to explode here Poundcake is you! Lol.

Put the bottle down Tommy. I think you've had enough.